Clinical Journal of the American Society of Nephrology (CJASN)
by American Society of Nephrology
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 7 chart positions in 7 markets.
By chart position
- 🇰🇷KR · Medicine#7010K to 30K
- 🇨🇭CH · Medicine#3410K to 30K
- 🇵🇭PH · Medicine#763K to 10K
- 🇵🇪PE · Medicine#108500 to 3K
- 🇹🇭TH · Medicine#110500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
13K to 41K🎙 Weekly cadence·199 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
25K to 82K🇰🇷37%🇨🇭37%🇵🇭12%+4 more - Active Followers
Loyal subscribers who consistently listen
7.5K to 25K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Not detected.
Recent guests
Recent episodes
A Target Trial Emulation of GLP1RA, SGLT2i or DPP4i as Add on Treatment in CKD
Jun 17, 2026
Unknown duration
Total Kidney Volume and eGFR in Polycystic Kidney Disease
May 18, 2026
3m 54s
Proteomic Markers of Dietary Patterns and Chronic Kidney Disease
Apr 16, 2026
4m 50s
Long-Term Results of the ILLUMINATE-A Trial of Lumasiran for Primary Hyperoxaluria Type 1
Mar 18, 2026
3m 54s
Finerenone and eGFR Slope
Feb 26, 2026
3m 00s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/17/26 | A Target Trial Emulation of GLP1RA, SGLT2i or DPP4i as Add on Treatment in CKD | In this podcast, Drs. Roumie and Hung summarize the main findings from their study on "Target Emulation Trial: GLP1RA, SGLT2i, DPP4i for Kidney Outcome Prevention" on behalf of their colleagues. | — | ||||||
| 5/18/26 | Total Kidney Volume and eGFR in Polycystic Kidney Disease✨ | kidney diseasepolycystic kidney disease+3 | Dr. Yu | American Society of NephrologyRelationship between Total Kidney Volume and eGFR in Autosomal Dominant Polycystic Kidney Disease | — | kidney volumeeGFR+3 | — | 3m 54s | |
| 4/16/26 | Proteomic Markers of Dietary Patterns and Chronic Kidney Disease✨ | dietary patternschronic kidney disease+4 | Dr. Rebholz | American Society of NephrologyProteomic Markers of Dietary Patterns, CKD Progression, and Mortality in the CRIC Study | — | proteomic markersdietary patterns+4 | — | 4m 50s | |
| 3/18/26 | Long-Term Results of the ILLUMINATE-A Trial of Lumasiran for Primary Hyperoxaluria Type 1✨ | clinical trialnephrology+3 | Dr. Saland | LumasiranILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1 | Primary Hyperoxaluria Type 1 | ILLUMINATE-ALumasiran+3 | — | 3m 54s | |
| 2/26/26 | Finerenone and eGFR Slope✨ | finerenoneeGFR slope+3 | Dr. McCausland | FINEARTS-HF | — | finerenoneeGFR+3 | — | 3m 00s | |
| 2/18/26 | Dynamic Risk Prediction of Deceased Donor Kidney Transplant Failure✨ | kidney transplantgraft failure+3 | Dr. ParikhDr. Malhotra+1 | American Society of NephrologyDynamic Risk Prediction of Graft Failure After Deceased Donor Kidney Transplant | — | kidney transplantgraft failure+5 | — | 4m 06s | |
| 12/18/25 | Early-Start vs. Late-Start Icodextrin in Pediatric Peritoneal Dialysis Patients✨ | pediatric nephrologyperitoneal dialysis+3 | Dagmara Borzych-DużałkaKhandelval | International Pediatric Peritoneal Dialysis Network | — | icodextrinperitoneal dialysis+3 | — | 6m 20s | |
| 10/28/25 | Comparative Effectiveness of Lubiprostone and Stool Softeners in CKD✨ | chronic kidney diseaselubiprostone+3 | Dr. Sumida | American Society of NephrologyComparative Effectiveness of Lubiprostone and Stool Softeners on Risk of Kidney Outcomes in Patients with CKD | — | CKDlubiprostone+3 | — | 3m 53s | |
| 9/30/25 | SGLT2 Inhibition and Hospitalizations in Patients with Chronic Kidney Disease✨ | SGLT2 inhibitionchronic kidney disease+3 | Dr. Neuen | American Society of NephrologySGLT2 inhibition and hospitalizations in patients with CKD: Data from CREDENCE and a meta-analysis of CKD progression trials | — | SGLT2chronic kidney disease+4 | — | 3m 47s | |
| 8/27/25 | Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative Glomerulonephritis✨ | kidney outcomesC3 glomerulopathy+3 | Dr. Ghaddar | American Society of NephrologyClinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative Glomerulonephritis | — | kidneyglomerulopathy+3 | — | 3m 09s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/25/25 | Perceptions of Future Earnings Among Nephrology Fellows✨ | nephrologyfellowship+3 | Drs. RaslanDr. Triozzi | American Society of NephrologyAssessing Current Nephrology Fellows' Perceptions of Future Earnings as Attending Physicians | — | nephrology fellowsfuture earnings+3 | — | 3m 03s | |
| 6/27/25 | SGLT2 Inhibitors and Risk of Urinary Tract Infections with Abnormal Genitourinary Pathology | In this podcast, Drs. Eadon, Zhang, and Xu summarize the main findings from their study on "Risk of Urinary Tract Infections with SGLT2 Inhibitors in Subpopulations with Abnormal Genitourinary Pathology" on behalf of their colleagues. | — | ||||||
| 4/23/25 | Transition Practices in Pediatric and Adult Nephrology | In this podcast, Dr. Vissing summarizes the main findings from his study on "Bridging the Gap: Assessing Nephrology Transition Practices in Pediatric and Adult Medical Centers" on behalf of his colleagues. | — | ||||||
| 3/25/25 | Creatinine and Cystatin-Based Equations in People with Cancer | In this podcast, Dr. Titan summarizes the main findings from her study on "Performance of creatinine and cystatin-based equations on estimating measured GFR in people with hematological and solid cancers" on behalf of her colleagues. | — | ||||||
| 2/14/25 | GLP1 Receptor Agonists and Kidney Outcomes | In this podcast, Dr. Mendonça summarizes the main findings from his study on "The Impact of Glucagon-like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials" on behalf of his colleagues. | — | ||||||
| 1/23/25 | Anticoagulation and Fracture Risk in CKD Patients with Atrial Fibrillation | In this podcast, Drs. Khan and Paik summarize the main findings from their study on "Fracture in association with anticoagulant therapy in patients with chronic kidney disease and atrial fibrillation" on behalf of their colleagues. | — | ||||||
| 12/23/24 | Comparing USRDS vs. National Death Index on Sudden Cardiac Death in Dialysis Patients | In this podcast, Dr. Shafi and Dr. Obi summarize the main findings from their study on "Comparing USRDS and National Death Index Data on Sudden Cardiac Death in US Dialysis Patients" on behalf of their colleagues. | — | ||||||
| 11/26/24 | Association of Kidney Function with SGLT2 Inhibitor Discontinuation | In this podcast, Dr. Estrella summarizes the main findings from her study on "Association of kidney function with SGLT2 inhibitor discontinuation among United States Veterans" on behalf of her colleagues. | — | ||||||
| 11/15/24 | Interview with 2024 CJASN Trainee of the Year – Second Place Awardee: Dr. Mohammad Azfar Qureshi | In this podcast, CJASN Editor-in-Chief Dr. Rhee interviewed Dr. Qureshi on the findings of his study "The Association of Intra-abdominal Adhesions with Peritoneal Dialysis Catheter-Related Complications." | — | ||||||
| 11/14/24 | Interview with 2024 CJASN Trainee of the Year – First Place Awardee: Dr. Christine Limonte | In this podcast, CJASN Editor-in-Chief Dr. Rhee interviewed Dr. Limonte on the findings of her study "Associations of Biomarkers of Tubular Injury and Inflammation with Biopsy Features in Type 1 Diabetes." | — | ||||||
| 10/21/24 | Providers' Experiences Discussing Alternatives to Kidney Replacement Therapy with Patients | In this podcast, Drs. Wong and Chotivatanapong summarize the main findings from their study on "Nephrology Providers' Experiences Discussing Care for Patients with Kidney Failure who Forgo Kidney Replacement Therapy: National Qualitative Study" | — | ||||||
| 9/23/24 | Editors Choice Articles: SGLT2 inhibitors in frailty, multimorbidity and polypharmacy; SGLT2 inhibitors and cardiovascular death; and mobile health technology in CKD management | CJASN editors highlight three articles centered on the theme of CKD, including articles on SGLT2 inhibitors in CKD patients; SGLT2 inhibitors and cardiovascular death in CKD; and smartphone intervention for lifestyle and hypertension management in CKD. | — | ||||||
| 8/16/24 | Fellows' Perspectives on Parental Leave Policies and Family Planning | In this podcast, Dr. Kendrick and Dr. Dixon summarize the main findings from their study on "A National Survey of Pregnancy and Parenthood Among Nephrology Trainees: A Focus on Nephrology Fellowship" on behalf of their colleagues. | — | ||||||
| 8/1/24 | Editors' Choice Articles: Pediatric ESKD iron stores, Impact of hemodiafiltration and hemodialysis on β-2-microglobulin, and Novel instruments for dialysis modality awareness | Drs. Rhee, Roshanravan, and Nigwekar highlight three cutting-edge dialysis articles on pediatric ESKD iron store biomarkers; HDF, HD, and β-2-microglobulin kinetics; and development of a novel kidney replacement therapy awareness instrument. | — | ||||||
| 12/14/23 | Kidney Measures and Venous Thromboembolism | Dr. Zhong Zheng provides an overview of his study, "Association of Estimated Glomerular Filtration Rate and Albuminuria with Venous Thromboembolism," on behalf of his colleagues. | — | ||||||
Showing 25 of 202
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
7 placements across 7 markets.
Chart Positions
7 placements across 7 markets.